• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

    5/7/25 4:01:00 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MIRM alert in real time by email

    - First quarter 2025 total revenue of $111.6 million; 2025 guidance increased to $435 to $450 million

    - VISTAS study in PSC expected to complete enrollment in third quarter of 2025; topline data expected in second quarter of 2026

    - LIVMARLI oral tablet formulation FDA approved

    - Conference call to provide business updates today, May 7 at 1:30 p.m. PT/4:30 p.m. ET

    Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the first quarter 2025 and provided a business update.

    "It's been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline," said Chris Peetz, chief executive officer of Mirum. "We're pleased with the FDA's approval of LIMARLI's tablet formulation, which provides more options for the ALGS and PFIC community in the U.S. in the form of a convenient single tablet dose. Our VISTAS study of volixibat in PSC is enrolling well and we expect to complete enrollment in the third quarter of this year. We're excited to continue our strong execution across our commercial medicines and pipeline throughout the year."

    Commercial: Raising full year revenue guidance to $435 to $450 million

    • First quarter 2025 global net product sales of $111.6 million.
    • First quarter 2025 LIVMARLI net product sales were $73.2 million representing 71% growth over first quarter 2024 net product sales.
    • Bile Acid Medicines net product sales were $38.4 million representing 47% growth over first quarter 2024 net product sales.
    • LIVMARLI oral tablet formulation approved.
    • LIVMARLI approved in Japan for ALGS and PFIC.
    • CTEXLI (chenodiol) approved in the US for cerebrotendinous xanthomatosis.

    Regulatory and Pipeline: Clinical milestones on track

    • Volixibat VISTAS study in primary sclerosing cholangitis (PSC) expected to complete enrollment in third quarter of 2025; topline data expected in the second quarter of 2026.
    • Oral presentation of 28-week interim data from volixibat in PBC (VANTAGE study) at EASL on Friday May 9th at 9:30am CEST.
    • Volixibat VANTAGE study in primary biliary cholangitis (PBC) expected to complete enrollment in 2026.
    • LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions expected to complete enrollment in 2026.
    • Expect to initiate Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS) in 2025.

    Corporate and Financial: Strong balance sheet and financial independence

    • Total revenue for the quarter ended March 31, 2025, was $111.6 million compared to $69.2 million for the quarter ended March 31, 2024.
    • Total operating expenses were $126.8 million for the quarter ended March 31, 2025 compared to $95.7 million for the quarter ended March 31, 2024.
    • Total operating expenses for the quarter ended March 31, 2025 included $21.9 million of non-cash stock-based compensation, intangible amortization, and other non-cash expenses compared to $17.1 million for the quarter ended March 31, 2024.
    • As of March 31, 2025, Mirum had unrestricted cash, cash equivalents and investments of $298.6 million compared to $292.8 million as of December 31, 2024.

    Business Update Conference Call

    Mirum will host a conference call today, May 7th at 1:30 p.m. PT/4:30 p.m. ET, to provide business updates. Join the call using the following details:

    Conference Call Details:

    U.S./Toll-Free: +1 833 470 1428

    International: +1 404 975 4839

    Passcode: 549600

    You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days.

    About LIVMARLI® (maralixibat) oral solution and LIVMARLI® (maralixibat) tablets

    LIVMARLI® (maralixibat) oral solution is an orally administered, ileal bile acid transporter (IBAT) inhibitor approved by the U.S. Food and Drug Administration for two pediatric cholestatic liver diseases. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. three months of age and older and in Europe for patients two months of age and older. It is also approved in the U.S. for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) 12 months of age and older and in Europe for the treatment of PFIC in patients three months of age and older. For more information for U.S. residents, please visit LIVMARLI.com.

    LIVMARLI has received orphan designation for ALGS and PFIC. LIVMARLI is currently being evaluated in the Phase 3 EXPAND study in additional settings of cholestatic pruritus. To learn more about ongoing clinical trials with LIVMARLI, please visit Mirum's clinical trials section on the company's website.

    IMPORTANT SAFETY INFORMATION

    Limitation of Use: LIVMARLI is not for use in PFIC type 2 patients who have a severe defect in the bile salt export pump (BSEP) protein.

    LIVMARLI can cause side effects, including

    Liver injury. Changes in certain liver tests are common in patients with ALGS and PFIC but can worsen during treatment. These changes may be a sign of liver injury. In PFIC, this can be serious or may lead to liver transplant or death. Your healthcare provider should do blood tests and physical exams before starting and during treatment to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including nausea or vomiting, skin or the white part of the eye turns yellow, dark or brown urine, pain on the right side of the stomach (abdomen), bloating in your stomach area, loss of appetite or bleeding or bruising more easily than normal.

    Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain. Your healthcare provider may advise you to monitor for new or worsening stomach problems including stomach pain, diarrhea, blood in your stool or vomiting. Tell your healthcare provider right away if you have any of these symptoms more often or more severely than normal for you.

    A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat is common in patients with Alagille syndrome and PFIC but may worsen during treatment. Your healthcare provider should do blood tests before starting and during treatment and may monitor for bone fractures and bleeding which have been reported as common side effects.

    US Prescribing Information

    EU SmPC

    Canadian Product Monograph

    About Volixibat

    Volixibat is an oral, minimally absorbed agent designed to selectively inhibit the ileal bile acid transporter (IBAT). Volixibat may offer a novel approach in the treatment of adult cholestatic diseases by blocking the recycling of bile acids, through inhibition of IBAT, thereby reducing bile acids systemically and in the liver. Volixibat is currently being evaluated in Phase 2b studies for primary sclerosing cholangitis (PSC) (VISTAS study), and primary biliary cholangitis (PBC) (VANTAGE study). In June, Mirum announced positive interim results from the Phase 2b VANTAGE study showing statistically significant improvement in pruritus as well as meaningful reductions in serum bile acids and improvements in fatigue for patients treated with volixibat. No new safety signals were observed, and the most common adverse event was diarrhea with all cases mild to moderate. Volixibat has been granted breakthrough therapy designation for the treatment of PBC.

    About CHOLBAM® (cholic acid) capsules

    The FDA approved CHOLBAM (cholic acid) capsules in March 2015, the first FDA-approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisome biogenesis disorder-Zellweger spectrum disorder. The effectiveness of CHOLBAM has been demonstrated in clinical trials for bile acid synthesis disorders and the adjunctive treatment of peroxisomal disorders. An estimated 200 to 300 patients are current candidates for therapy.

    CHOLBAM® (cholic acid) Indication

    CHOLBAM is a bile acid indicated for

    • Treatment of bile acid synthesis disorders due to single enzyme defects.
    • Adjunctive treatment of peroxisomal disorders, including Zellweger spectrum disorders, in patients who exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat-soluble vitamin absorption.

    LIMITATIONS OF USE

    The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to single enzyme defects or peroxisomal disorders, including Zellweger spectrum disorders, have not been established.

    IMPORTANT SAFETY INFORMATION

    WARNINGS AND PRECAUTIONS – Exacerbation of liver impairment

    Monitor liver function and discontinue CHOLBAM in patients who develop worsening of liver function while on treatment.

    Concurrent elevations of serum gamma glutamyltransferase (GGT) and alanine aminotransferase (ALT) may indicate CHOLBAM overdose.

    Discontinue treatment with CHOLBAM at any time if there are clinical or laboratory indicators of worsening liver function or cholestasis.

    ADVERSE REACTIONS

    The most common adverse reactions (≥1%) are diarrhea, reflux esophagitis, malaise, jaundice, skin lesion, nausea, abdominal pain, intestinal polyp, urinary tract infection, and peripheral neuropathy.

    Please see full Prescribing Information for additional Important Safety Information.

    About CTEXLI™ (chenodiol) tablets

    CTEXLI™ (chenodiol) tablets is FDA-approved for the treatment of adults with cerebrotendinous xanthomatosis (CTX). Chenodiol is another name for chenodeoxycholic acid (CDCA). CDCA is a naturally occurring bile acid that was originally approved for the treatment of people with radiolucent stones in the gallbladder. CTEXLI was evaluated as part of the Phase 3 RESTORE study, the first and only clinical trial for CTX. CTX is a rare progressive disease that can affect the brain, spinal cord, tendons, eyes and arteries.

    IMPORTANT SAFETY INFORMATION

    CTEXLI can cause side effects, including:

    Liver Injury: You will need to undergo laboratory testing before starting and while taking CTEXLI to check your liver function. Changes in certain liver tests may occur during treatment and may be a sign of liver injury. This can be serious. Stop taking CTEXLI immediately and tell your healthcare provider right away if you get any signs or symptoms of liver problems, including, stomach (abdomen) pain, bruising, dark-colored urine, feeling tired (fatigue), bleeding, yellowing of the skin and eyes, nausea, and itching.

    Most Common Side Effects: Diarrhea, headache, stomach pain, constipation, high blood pressure, muscular weakness, and upper respiratory tract infection.

    Tell your healthcare provider about all the medications that you take, as CTEXLI may interact with other medicines.

    US Prescribing Information

    About Mirum Pharmaceuticals

    Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution and LIVMARLI® (maralixibat) tablets, CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.

    LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum has initiated the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.

    Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.

    To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, significant increase or continued commercial results for our approved medicines, including continued financial growth, the potential achievement of our yearly financial guidance, continued strong execution across our approved medicines and pipeline, the results, enrollment, conduct and progress of our ongoing and planned studies for our product candidates, the timing and results of interim analyses of our ongoing studies and the regulatory approval path for our product candidates in any indication or any specific territory. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "expected," "will," "could," "would," "guidance," "potential," "continue" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum's business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Mirum's Annual Report for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 26, 2025, and subsequent filings with the Securities and Exchange Commission, which are available at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

    Mirum Pharmaceuticals, Inc.

    Condensed Consolidated Statement of Operations Data

    (in thousands, except share and per share amounts)

    (Unaudited)

     

     

     

    Three Months Ended March 31,

     

     

    2025

     

    2024

     

     

     

    Revenue:

     

     

     

     

    Product sales, net

     

    $

    111,585

     

     

    $

    68,917

     

    License and other revenue

     

     

    —

     

     

     

    305

     

    Total revenue

     

     

    111,585

     

     

     

    69,222

     

    Operating expenses:

     

     

     

     

    Cost of sales (1)

     

     

    23,018

     

     

     

    17,830

     

    Research and development

     

     

    46,044

     

     

     

    32,222

     

    Selling, general and administrative

     

     

    57,706

     

     

     

    45,638

     

    Total operating expenses (2)

     

     

    126,768

     

     

     

    95,690

     

    Loss from operations

     

     

    (15,183

    )

     

     

    (26,468

    )

    Other income (expense):

     

     

     

     

    Interest income

     

     

    3,023

     

     

     

    3,633

     

    Interest expense

     

     

    (3,596

    )

     

     

    (3,577

    )

    Other income, net

     

     

    2,108

     

     

     

    1,757

     

    Net loss before provision for income taxes

     

     

    (13,648

    )

     

     

    (24,655

    )

    Provision for income taxes

     

     

    1,029

     

     

     

    624

     

    Net loss

     

     

    (14,677

    )

     

     

    (25,279

    )

     

     

     

     

     

    Net loss per share, basic and diluted

     

    $

    (0.30

    )

     

    $

    (0.54

    )

    Weighted-average shares of common stock outstanding, basic and diluted

     

     

    48,889,058

     

     

     

    46,927,550

     

     

     

     

     

     

     

     

     

     

     

    (1) Amounts include intangible amortization expense as follows:

     

     

     

     

     

     

     

     

     

    Intangible amortization

     

    $

    5,893

     

     

    $

    5,402

     

     

     

     

     

     

    (2) Amounts include stock-based compensation expense as follows:

     

     

     

     

     

     

     

     

     

    Cost of sales

     

    $

    331

     

     

    $

    —

     

    Research and development

     

     

    5,229

     

     

     

    3,861

     

    Selling, general and administrative

     

     

    10,243

     

     

     

    7,589

     

    Total stock-based compensation

     

    $

    15,803

     

     

    $

    11,450

     

    Mirum Pharmaceuticals, Inc.

    Condensed Consolidated Balance Sheet Data

    (in thousands)

    (Unaudited)

         

     

    March 31,

     

     December 31,

     

    2025

     

    2024

     

     

     

     

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    211,822

     

     

    $

    222,503

     

    Short-term investments

     

    65,852

     

     

     

    57,812

     

    Accounts receivable

     

    95,852

     

     

     

    78,286

     

    Inventory

     

    22,418

     

     

     

    22,403

     

    Prepaid expenses and other current assets

     

    14,874

     

     

     

    11,784

     

    Total current assets

     

    410,818

     

     

     

    392,788

     

    Restricted cash

     

    425

     

     

     

    425

     

    Long-term investments

     

    20,912

     

     

     

    12,526

     

    Intangible assets, net

     

    243,845

     

     

     

    249,819

     

    Other noncurrent assets

     

    14,245

     

     

     

    15,196

     

    Total assets

    $

    690,245

     

     

    $

    670,754

     

    Liabilities and Stockholders' Equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    11,639

     

     

    $

    14,618

     

    Accrued expenses and other current liabilities

     

    115,938

     

     

     

    111,933

     

    Total current liabilities

     

    127,577

     

     

     

    126,551

     

    Operating lease liabilities, noncurrent

     

    7,003

     

     

     

    7,972

     

    Convertible notes payable, net, noncurrent

     

    308,509

     

     

     

    308,082

     

    Other liabilities

     

    13,900

     

     

     

    2,509

     

    Total liabilities

     

    456,989

     

     

     

    445,114

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Preferred stock

     

    —

     

     

     

    —

     

    Common stock

     

    5

     

     

     

    5

     

    Additional paid-in capital

     

    892,367

     

     

     

    870,189

     

    Accumulated deficit

     

    (658,858

    )

     

     

    (644,181

    )

    Accumulated other comprehensive loss

     

    (258

    )

     

     

    (373

    )

    Total stockholders' equity

     

    233,256

     

     

     

    225,640

     

    Total liabilities and stockholders' equity

    $

    690,245

     

     

    $

    670,754

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250507261079/en/

    Investor Contact:

    Andrew McKibben

    [email protected]

    Media Contact:

    Erin Murphy

    [email protected]

    Get the next $MIRM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MIRM

    DatePrice TargetRatingAnalyst
    4/17/2024$48.00Buy
    Stifel
    12/18/2023$60.00 → $58.00Buy
    H.C. Wainwright
    11/20/2023$37.00Overweight
    Analyst
    11/13/2023$60.00Overweight
    Morgan Stanley
    10/24/2023$50.00Overweight
    Cantor Fitzgerald
    10/17/2023$62.00Outperform
    Evercore ISI
    9/20/2023$70.00Mkt Outperform
    JMP Securities
    9/1/2022$38.00Buy
    Citigroup
    More analyst ratings

    $MIRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, GLOBAL CONTROLLER Howe Jolanda sold $107,343 worth of shares (2,415 units at $44.45), decreasing direct ownership by 50% to 2,426 units (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/19/25 5:40:09 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, GLOBAL CONTROLLER Howe Jolanda exercised 58,215 shares at a strike of $2.67 and sold $2,554,763 worth of shares (57,606 units at $44.35), increasing direct ownership by 14% to 4,841 units (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/18/25 9:30:09 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND COO Radovich Peter converted options into 14,440 shares and sold $348,364 worth of shares (7,879 units at $44.21), increasing direct ownership by 54% to 18,672 units (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/18/25 9:30:07 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Financials

    Live finance-specific insights

    See more
    • Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      - First quarter 2025 total revenue of $111.6 million; 2025 guidance increased to $435 to $450 million - VISTAS study in PSC expected to complete enrollment in third quarter of 2025; topline data expected in second quarter of 2026 - LIVMARLI oral tablet formulation FDA approved - Conference call to provide business updates today, May 7 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the first quarter 2025 and provided a business update. "It's been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline," said Chris Peetz, chief executive officer of Mirum. "We're pleased with the FD

      5/7/25 4:01:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report first quarter 2025 financial results on Wednesday, May 7, 2025. Mirum will also host a conference call to discuss the first quarter 2025 financial results and recent corporate progress. Conference call details: Wednesday, May 7, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: + 1 833 470 1428 International: + 1 404 975 4839 Passcode: 549600 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company d

      4/30/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

      - 2024 net product sales of $336.4 million - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in PSC expected to complete enrollment in second half 2025; topline data expected 2026 - CTEXLI (chenodiol) approved in the US for cerebrotendinous xanthomatosis - Conference call to provide business updates today, February 26 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update. "2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue," said Chris Pee

      2/26/25 4:01:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    SEC Filings

    See more

    $MIRM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 10-Q filed by Mirum Pharmaceuticals Inc.

      10-Q - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)

      5/7/25 4:08:12 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)

      5/7/25 4:02:22 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mirum Pharmaceuticals Inc.

      SCHEDULE 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      5/7/25 10:57:01 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

      SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      11/14/24 4:37:52 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

      SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      11/14/24 12:55:40 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

      SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      11/14/24 12:25:52 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL

      - 28-week data from the Phase 2b VANTAGE PBC study highlights statistically significant improvements in pruritus and numeric improvements in fatigue, the two most burdensome symptoms of PBC - Seventy percent of patients treated with volixibat experienced a ≥50% reduction in serum bile acids - Volixibat treated patients experienced reductions in IL-31 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today presented new data from its Phase 2b VANTAGE study at the European Association for the Study of the Liver (EASL) meeting in Amsterdam, the Netherlands. The VANTAGE study is evaluating volixibat in patients with cholestatic pruritus caused by primary biliary cholangitis (PBC). "The extended VAN

      5/9/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      - First quarter 2025 total revenue of $111.6 million; 2025 guidance increased to $435 to $450 million - VISTAS study in PSC expected to complete enrollment in third quarter of 2025; topline data expected in second quarter of 2026 - LIVMARLI oral tablet formulation FDA approved - Conference call to provide business updates today, May 7 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the first quarter 2025 and provided a business update. "It's been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline," said Chris Peetz, chief executive officer of Mirum. "We're pleased with the FD

      5/7/25 4:01:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report first quarter 2025 financial results on Wednesday, May 7, 2025. Mirum will also host a conference call to discuss the first quarter 2025 financial results and recent corporate progress. Conference call details: Wednesday, May 7, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: + 1 833 470 1428 International: + 1 404 975 4839 Passcode: 549600 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company d

      4/30/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $MIRM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • February 21, 2025 - FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disease

      For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato

      2/21/25 11:48:20 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $24,214 worth of shares (549 units at $44.11) (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/18/25 5:04:31 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $99,518 worth of shares (2,298 units at $43.31) (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/12/25 4:51:20 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $83,661 worth of shares (1,915 units at $43.69) (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/10/25 5:12:58 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on Mirum Pharmaceuticals with a new price target

      Stifel initiated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $48.00

      4/17/24 7:27:53 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Mirum Pharmaceuticals with a new price target

      H.C. Wainwright reiterated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $58.00 from $60.00 previously

      12/18/23 11:54:26 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Analyst resumed coverage on Mirum Pharmaceuticals with a new price target

      Analyst resumed coverage of Mirum Pharmaceuticals with a rating of Overweight and set a new price target of $37.00

      11/20/23 7:48:18 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Leadership Updates

    Live Leadership Updates

    See more
    • Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

      - 2024 net product sales of approximately $336 million exceeds upper end of guidance range; preliminary and unaudited estimate - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in primary sclerosing cholangitis expected to complete enrollment in second half 2025; topline data expected 2026 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today provided its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, corporate updates, and full-year 2025 outlook. "2024 marked a significant year for Mirum as we accelerated our commercial business and achieved significant development milestones," said Chris

      1/13/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

      SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

      3/25/24 7:00:00 AM ET
      $IPSC
      $MIRM
      $RPHM
      $SGMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer

      Se NodThera Ltd ("NodThera" or the "Company") NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin, M.D., M.Sc., FMH as Chief Medical Officer (CMO), with effect from today. With more than 20 years of experience across global large pharma, biotech and academic medicine, Dr. Jaecklin is an accomplished late-stage drug development leader. He brings deep expertise across multiple therapy areas, including neuroscience and inflammation, with a strong track reco

      2/5/24 7:00:00 AM ET
      $GLPG
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care